OAK BROOK, Ill.--(BUSINESS WIRE)--June 16, 2006--Bio-Bridge Science, Inc. (OTCBB: BGES - News), a developer of vaccines with broad preventative and therapeutic applications, today announced that the Beijing Institute of Radiation Medicine has notified the Company that it has completed the planned pre-clinical safety and immunogenicity studies for Bio-Bridge’s oral HIV vaccine. In early February, Bio-Bridge Science received encouraging initial results of the pre-clinical trials. Final results show no toxicity was observed in the animals orally administered with the HIV vaccine. There is no indication that vaccine DNA integrates into host genome and passes through placenta barrier. The immunogenicity study in monkeys shows that the vaccine induces HIV-1 gp41-specific serum antibodies (IgG) and intestinal and vaginal antibodies (sIgA). The sera, intestinal and vaginal washings neutralize HIV-1 primary isolate in vitro. The vaccine also induces HIV-1 Gag-specific T cells in the vaccinated monkeys.
